Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

SRR1396640

GTEX

dab17d2f-7234-59e2-8d45-08e65c3fafc4

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
GTEX
cancer_type_detailed
subtype
cancer_type
GTEX
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • KRAS_SIGNALING_DN+0.500
  • PANCREAS_BETA_CELLS+0.446
  • HEDGEHOG_SIGNALING+0.315
  • ESTROGEN_RESPONSE_EARLY+0.298
  • ESTROGEN_RESPONSE_LATE+0.256
  • MYOGENESIS+0.223
  • BILE_ACID_METABOLISM+0.190
  • SPERMATOGENESIS+0.184
  • UV_RESPONSE_DN+0.173
  • WNT_BETA_CATENIN_SIGNALING+0.157

Top 10 suppressed

  • MYC_TARGETS_V1-0.668
  • UNFOLDED_PROTEIN_RESPONSE-0.541
  • E2F_TARGETS-0.531
  • MYC_TARGETS_V2-0.499
  • PROTEIN_SECRETION-0.496
  • DNA_REPAIR-0.491
  • OXIDATIVE_PHOSPHORYLATION-0.442
  • MTORC1_SIGNALING-0.441
  • G2M_CHECKPOINT-0.430
  • INTERFERON_ALPHA_RESPONSE-0.390

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR1331751
brain-umap@2
GTEX0.964
2SRR1471350
brain-umap@2
GTEX0.953
3SRR1337909
brain-umap@2
GTEX0.946
4SRR1337864
brain-umap@2
GTEX0.945
5SRR1485542
brain-umap@2
GTEX0.944
6SRR1311575
brain-umap@2
GTEX0.943
7SRR1352975
brain-umap@2
GTEX0.942
8SRR1314958
brain-umap@2
GTEX0.942
9SRR1500868
brain-umap@2
GTEX0.940
10SRR1431307
brain-umap@2
GTEX0.938

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 15 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
KRAS_SIGNALING_DN0.500Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.446Cobimetinib— uncovered
HEDGEHOG_SIGNALING0.315Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.298Inavolisib— uncovered
ESTROGEN_RESPONSE_LATE0.256Idelalisib— uncovered
MYOGENESIS0.223Inavolisib— uncovered
BILE_ACID_METABOLISM0.190Inavolisib— uncovered
SPERMATOGENESIS0.184Inavolisib— uncovered
UV_RESPONSE_DN0.173Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.157Inavolisib— uncovered
APICAL_SURFACE0.154Temsirolimus— uncovered
APICAL_JUNCTION0.135Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.057Inavolisib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.052Inavolisib— uncovered
NOTCH_SIGNALING0.039Inavolisib— uncovered